This research is something that will either matter quite a bit or not at all. Frankly, it’s premature at this point. A team at King’s College Hospital in London just published a case report describing a patient who developed acute psychosis five months after starting ruxolitinib. Before we go any further, we need to […]
Myelofibrosis, New Markers of Disease Progression
Simple Summary Disease progression and prognosis in PMF are usually associated with worsening of anemia, increase of circulating blasts, and, more recently, with the presence, in addition to the “classical” driver mutations, of JAK2, MPL, and CALR genes, as well as of cytogenetic and molecular abnormalities that have been incorporated into new genetically based prognostic scoring systems. We have […]
Patients are Asking – MPN Expert Dr. Prithviraj Bose
Episode 1 of 3 in Patients are Asking Series What symptoms should I look for to see if I might be progressing from polycythemia vera to myelofibrosis? When would you typically recommend Next Generation Sequencing (NGS) and what are the benefits? Why does bone & joint pain occur and what are some possible solutions? Dr. […]
Fedratinib newly approved treatment for Myelofibrosis patients
Moshe Talpaz 1, Jean-Jacques Kiladjian 2 – Received: 14 February 2020 / Revised: 15 June 2020 / Accepted: 25 June 2020 © The Author(s) 2020. This article is published with open access Abstract Myeloproliferative neoplasm (MPN)-associated myelofibrosis (MF) is characterized by cytopenias, marrow fibrosis, constitutional symptoms, extramedullary hematopoiesis, splenomegaly, and shortened survival. Constitutive activation of […]
